# Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

> **NCT05865041** · PHASE2 · UNKNOWN · sponsor: **ASLAN Pharmaceuticals** · enrollment: 60 (estimated)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** Farudodstat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05865041
- **Lead sponsor:** ASLAN Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-14
- **Primary completion:** 2024-09-12
- **Final completion:** 2024-10-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05865041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05865041, "Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05865041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*